Double-Targeting CAR-T cells aim to outsmart lymphoma relapse
Disease control
Ongoing
This phase 2 trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on lymphoma cells, aiming to prevent the cancer from escaping treatment. It involves 100 adults with relapsed or refractory large B-cell lymphoma who have not responded to standard…
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC